31 results about "Positive patient" patented technology

Techniques are provided for controlling spinal cord stimulation (SCS) or other forms of neurostimulation. In one example, SCS treatment is delivered to a patient and nerve impulse firing signals are sensed along the spinal cord following the SCS treatment. The nerve impulse signals are analyzed to determine whether the signals are associated with effective SCS and then the delivery of additional SCS is controlled to improve SCS efficacy. For example, the nerve impulse signals can be analyzed to determine whether the signals are consistent with a positive patient mood associated with pain mitigation and, if not, SCS control parameters are adjusted to improve the efficacy of the SCS in reducing pain. In other examples, heart rate variability (HPV) is also used to control SCS. Still further, adjustments may be made to SCS control parameters to improve antiarrhythmic or sympatholytic effects associated with SCS. Techniques employing baseline / target calibration procedures are also described.

Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.

Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice and IL-2 responses in 52-73% of HIV positive, flu positive patients (cluster peptides), were co-linearly synthesized with the peptide 18 of the V3 loop of HIV-1 gp 160, corresponding to the principal neutralizing determinant of HIV-IIIB and also shown to contain a dominant CTL epitope. Cognate help for peptide 18 antibody was elicited following a single immunization in all strains of mice which had previously responded to a T cell epitope encompassed by the peptides. In two strains of mice, the level of neutralizing antibody achieved was comparable to levels adequate for protection from homologous viral challenge in chimpanzees. After a single boost, much higher antibody titers for 90% neutralization in the range of 1:1000 to 1:16,000 were achieved. Spleen cells from mice of three distinct MHC haplotypes sharing the Dd class I MHC molecule but with different class II molecules, immunized with the compound peptides, exhibited enhanced gp160-specific CTL activity.

Techniques are provided for controlling spinal cord stimulation (SCS) or other forms of neurostimulation. In one example, SCS treatment is delivered to a patient and nerve impulse firing signals are sensed along the spinal cord following the SCS treatment. The nerve impulse signals are analyzed to determine whether the signals are associated with effective SCS and then the delivery of additional SCS is controlled to improve SCS efficacy. For example, the nerve impulse signals can be analyzed to determine whether the signals are consistent with a positive patient mood associated with pain mitigation and, if not, SCS control parameters are adjusted to improve the efficacy of the SCS in reducing pain. In other examples, heart rate variability (HRV) is also used to control SCS. Still further, adjustments may be made to SCS control parameters to improve antiarrhythmic or sympatholytic effects associated with SCS. Techniques employing baseline / target calibration procedures are also described.

It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.

The present invention provides a CTL inducer composition which comprises one or more peptides selected from the group consisting of the peptides of SEQ ID NOS: 1 to 27 in the Sequence Listing, and can be used for the treatment or prevention of cancer or a hepatitis C virus-related disease in two or more patient groups selected from the group consisting of an HLA-A2 positive patient group, an HLA-A24 positive patient group, an HLA-A26 positive patient group, and an HLA-A3 supertype positive patient group.

We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

The present invention provides a CTL inducer composition which comprises one or more peptides selected from the group consisting of the peptides of SEQ ID NOS: 1 to 27 in the Sequence Listing, and can be used for the treatment or prevention of cancer or a hepatitis C virus-related disease in two or more patient groups selected from the group consisting of an HLA-A2 positive patient group, an HLA-A24 positive patient group, an HLA-A26 positive patient group, and an HLA-A3 supertype positive patient group.

The invention discloses a health-care tea and a preparation method thereof. The health-care tea is prepared from the following raw materials by weight: 18-22 kg of negundo chastetree fruit, 15-25 kg of semen cassiae, 10-15 kg of chastetree fruit, 15-25 kg of fruits of slovenia dulcis, 20-30 kg of glossy privet fruit, 15-25 kg of red date, 9-11 kg of codonopsis pilosula, 15-25 kg of medlar, 4-6 kg of great burdock achene, 18-22 kg of radix astragali, 20-30 kg of cherokee rose fruit and 1-5 kg of chrysanthemum, wherein the raw materials are cleaned respectively, air-dried, then baked, sterilized, ground and finally packaged into tea bags. The health-care tea has excellent color, smell, taste and form, is mellow and fragrant, induces saliva, slakes thirst, is refreshing, invigorates the vitality, has the effects of clearing intestinal toxin, managing intestine and stomach, enriching blood, invigorating vital energy, nourishing kidney, dispelling wind, eliminating dampness and nourishing and protecting liver, and is particularly suitable for people who drink and smoke more and stay up late frequently, HBsAg, HBeAg and Anti-HBc positive and HBsAg, Anti-HBe and Anti-HBc positive patients and sub-health people due to environmental pollution.

The invention discloses a hepatitis C virus HVR1 (Hypervariable Region 1) fusion antigen. An amino acid sequence of the fusion antigen is shown as SEQ ID No.1. The invention also discloses application of the fusion antigen in preparation of a hepatitis C virus HVR1 antibody detection kit. The experiment proves that the cross reactivity of the fusion antigen is obviously improved compared with that of a single segment HVR1 antigen, and the detection coincidence rate of hepatitis C virus RNA positive patients is 99 percent. Because the HVR1 is a main neutralizing antigen epitope in the hepatitis C virus, the antigen can be used for achieving an aim of comprehensively detecting HCV infection for hepatitis C virus HVR1 antibody detection and effectively solving the problems such as outcome and prognosis of HCV diseases and prediction of interferon curative effect and has extremely great clinical application prospects.

The invention discloses broad spectrum or multivalent anti-HPV-L1 and E6 / E7-IgY, a small molecule antibody, a preparation method, a composition and application thereof. The genetic recombination technology is adopted to prepare prophylactic broad spectrum anti-HPV-L1-IgY and therapeutic broad spectrum or multivalent anti-HPV-E6 / E7-IgY and the small molecule antibody, and the broad spectrum or multivalent anti-HPV small molecule antibody is subjected to long-term modification with liposomes and cell penetrating peptides coupled. The invention also provides a liquid crystal microcapsule, a gel,a suppository, a cream, a lotion, a tablet, an effervescent tablet, a capsule, a soft capsule and an injection prepared by the broad spectrum or multivalent anti-HPV-IgY, the small molecule antibody and the composition, as well as the application in drugs, disinfectants, health products and medical devices for prevention and treatment of human papillomavirus (HPV) infections. The majority of HPV infections can be prevented, and HPV-infected positive patients can be treated to achieve the positive-to-negative conversion effect.

The "an oral powder for treating hepatitis B" of the present invention has strict compatibility. The curative effect is definite in the treatment of hepatitis B virus carriers or patients with hepatitis B, improving the self-immunity of hepatitis B patients, rapidly reducing enzymes, and repairing damaged liver cells. After being taken by more than a thousand patients, no virus mutation was found in one case; the negative conversion rate for patients with large and small three yang Compared with similar drugs, it is relatively improved, up to about 60%.

A medicament for treating HPV infection and an application of the medicament in the preparation of medicaments for treating HPV infection. The invention is characterized in that the active component of the medicament is rabies vaccine for human, and a pharmaceutically-acceptable carrier is added to prepare the medicament; the invention also provides an application of the medicament in the preparation of medicaments for treating HPV infection, that is, a new application of rabies vaccine for human in the preparation of medicaments for treating human papillomavirus infection. The medicament (rabies vaccine for human) for treating human papillomavirus infection provided by the invention has obvious treatment effect on human papillomavirus infection; through animal experiments and preclinical observation, the medicament has satisfied and beneficial effect, has the characteristics of safety, effectiveness, and difficult recurrence after cure, and has a treatment negative conversion rate of up to 90% for human papillomavirus infection positive patients.

The present invention provides methods of preventing or delaying the development of cancer (e.g., breast cancer) in BRCA1 mutation positive patients by beginning progesterone receptor antagonist treatment at an early age (e.g., by age 35, 30, or 25). In certain embodiment, such early treatment is long-term treatment, which may substitute or delay a preventative ovariectomy, single or double mastectomy (e.g., in patients wishing to delay or avoid a mastectomy, or patients that cannot afford a mastectomy).

The invention discloses a methylation site for cervical cancer screening. The methylation site is a cg24575234 site of a CHRM2 gene, a cg06818777 site of a CHAD gene, a cg08361126 site of an FGF10 gene, and a cg08976810 site of an ITGA8 gene. The invention also discloses a primer pair included in a kit for detecting a methylation level of a sample gene of cervical cancer. According to the invention, a whole process can be automated, the result is objective and is easy to interpret, and the influence of subjective factors is avoided; and the specificity of the methylation site, provided by theinvention, for detecting and screening cervical cancer is 100%, which is greater than the specificity (80%) of an HPV gene detection method, and the positive prediction value is increased from 0.0474%to 100%, so that the screening result is objective and is easy to interpret. The methylation site provided by the invention can also be used in parallel with a current cervical cancer screening experiment, thereby greatly saving the examination cost and avoiding economic losses and psychological burdens of too many false positive patients due to positive results.

We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and / or predictive biomarkers.

The invention discloses application of an L858R+V834L gene mutation primary tumor transplantation tumor model for a human non-small cell lung cancer. A transplantation tumor generated by the L858R+V834L gene mutation primary tumor transplantation tumor model for the human non-small cell lung cancer can be restrained by Iressa; the L858R+V834L gene mutation primary tumor transplantation tumor model provided by the invention can be used for screening a targeted drug for treating an EGRF (estimated glomerular filtration rate) mutation positive patient suffered from the non-small cell lung cancer; and an experimental technical platform is provided for the deep exploration of the action of epidermal growth factor receptor (EGFR) mutation generated in the non-small cell lung cancer.

The invention provides a method for screening a virus broad-spectrum neutral antibody and application thereof. The method comprises the following steps: preparing or providing a virus antigen protein; marking the virus antigen protein by using a fluorescence marker; preparing a cDNA (complementary deoxyribonucleic acid) template of a virus positive patient, designing primers, and amplifying the antibody gene; establishing a yeast antibody display library by using the obtained antibody gene; carrying out antigen protein mixed incubation on yeast cells in the obtained antibody display library and the obtained virus with the fluorescence marker, setting a cell separation door, and separating fluorescence positive yeast cells by a flow cytometry; and carrying out sequencing identification on the fluorescence positive yeast cells to obtain the virus broad-spectrum neutral antibody. The invention also provides a method for establishing an HIV (human immunodeficiency virus) virus antibody yeast display library and application thereof.

[Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test.[Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose α1→6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M−1 or more (at 25° C.) for an α1→6 fucose sugar chain No. 405. The fucose α1→6 affinitive lectin is preferably (2) a fucose α1→6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M−1 or less (at 25° C.) for a sugar chain No. 003 that does not contain α1→6 fucose and a glycolipid-type sugar chain No. 909 that does not contain α1→6 fucose.

A computer-implemented method for labeling and tracking a pathology specimen after collection and positive patient identification comprises the step of creating a pathology specimen record with a unique specimen identification code for at least one specimen. The method further includes the step of creating a label for application to a container holding the specimen, wherein the label includes the unique specimen identification code and creating an order with a unique accession number after the container is forwarded for processing, by scanning the label. The unique identification code is utilized for tracking purposes to ensure that pathology specimens for the positively identified patient are not lost in transit to the pathology laboratory for further processing. This improves quality to the patient by the elimination of transcription errors, identification of missing or lost specimens, and confirmation that pathology specimens are correctly matched to a patient.

The invention discloses a fusion antigen of the first hypervariable region of hepatitis C virus. The amino acid sequence of the fusion antigen is shown in SEQ ID No.1. The invention also discloses the detection of the fusion antigen in the preparation of hepatitis C virus HVR1 antibody. application in the kit. It is verified by experiments that the cross-reactivity of the fusion antigen of the present invention is significantly improved compared with the single fragment HVR1 antigen, and the detection coincidence rate with hepatitis C virus RNA-positive patients is as high as 99%. Since HVR1 is the main neutralizing epitope in hepatitis C virus, through the application of the antigen of the present invention, for the detection of hepatitis C virus HVR1 antibody, the purpose of comprehensive detection of HCV infection can be realized, and it can be used for the transformation of HCV disease. Problems such as reconciliation prognosis and interferon curative effect prediction can be effectively solved, and have great clinical application prospects.

Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.

The invention discloses a pair of primers for amplifying LINC02253 gene and application thereof, which is mainly used for detecting LINC02253 / GAPDH value by real-time fluorescence quantitative PCR oncolonoscopic sample or operation sample, if the ratio>=0. 00018 is positive, (0.00018 is negative. This method is an auxiliary diagnostic tool. Positive patients should be reexamined periodically if the pathological test is negative. At first, that PCR detection method is convenient, simple and suitable for hospital at all levels to popularize and use. The biopsy samples are helpful to determine the lesion and localize the tumor. Therefore, LINC02253 gene has high accuracy, specificity and practicability in the diagnosis of colorectal cancer.

Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.

The invention discloses a method for detecting pulmonary embolism. Absolute counting of platelet microparticles in blood plasma is detected to serve as auxiliary diagnosis of the pulmonary embolism bythe method based on standard flow cytometry. Through ROC curve analysis, the critical value of the platelet microparticles for diagnosing the pulmonary embolism is 716.90 per mu l; the sensitivity and the specificity at the critical value are respectively 58.82 percent and 95.92 percent. The positive likelihood ratio is 14.41, and the negative likelihood ratio is 0.43. The positive predictive value is 93.75 percent, and the negative predictive value is 69.12 percent; the Youden's index is 54.74 percent. The method is a non-invasive operation and is low in cost, easy to perform and high in specificity, and can further screen patients with a positive D-dimer result clinically, improves diagnostic specificity, and can serve as an evaluation means before CTPA examination is performed on a patient with the pulmonary embolism, so that adverse reactions caused by the CTPA examination are reduced, and the burden of the patient is lightened.